NEW YORK – Celsius Therapeutics said today that it has signed collaboration agreements with the Parker Institute for Cancer Immunotherapy, Institut Gustave Roussy in France, and the University Health Network in Toronto, Canada, under which it will use its proprietary single-cell genomics platform to test tissue samples from cancer patients receiving immune checkpoint inhibitor treatment.